DE69430317D1 - Wasserlösliche aktive sulfone von polyethylenglycolen - Google Patents
Wasserlösliche aktive sulfone von polyethylenglycolenInfo
- Publication number
- DE69430317D1 DE69430317D1 DE69430317T DE69430317T DE69430317D1 DE 69430317 D1 DE69430317 D1 DE 69430317D1 DE 69430317 T DE69430317 T DE 69430317T DE 69430317 T DE69430317 T DE 69430317T DE 69430317 D1 DE69430317 D1 DE 69430317D1
- Authority
- DE
- Germany
- Prior art keywords
- peg
- substances
- water
- soluble active
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
- C08G65/326—Polymers modified by chemical after-treatment with inorganic compounds containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/151,481 US5446090A (en) | 1993-11-12 | 1993-11-12 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
PCT/US1994/013013 WO1995013312A1 (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69430317D1 true DE69430317D1 (de) | 2002-05-08 |
DE69430317T2 DE69430317T2 (de) | 2002-10-02 |
Family
ID=22538958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69430317T Expired - Lifetime DE69430317T2 (de) | 1993-11-12 | 1994-11-14 | Wasserlösliche aktive sulfone von polyethylenglycolen |
Country Status (26)
Country | Link |
---|---|
US (6) | US5446090A (de) |
EP (2) | EP0728155B1 (de) |
JP (1) | JP3114998B2 (de) |
KR (1) | KR100225746B1 (de) |
CN (1) | CN1085689C (de) |
AT (1) | ATE215577T1 (de) |
AU (1) | AU687937B2 (de) |
BG (1) | BG63399B1 (de) |
BR (1) | BR9408048A (de) |
CA (1) | CA2176203C (de) |
CZ (1) | CZ295640B6 (de) |
DE (1) | DE69430317T2 (de) |
DK (1) | DK0728155T3 (de) |
EE (1) | EE03448B1 (de) |
ES (1) | ES2173943T3 (de) |
FI (1) | FI117441B (de) |
HK (1) | HK1042312A1 (de) |
HU (1) | HU225649B1 (de) |
NO (1) | NO315377B1 (de) |
NZ (1) | NZ276313A (de) |
PL (1) | PL180149B1 (de) |
RO (2) | RO121855B1 (de) |
RU (1) | RU2176253C2 (de) |
SK (1) | SK284527B6 (de) |
UA (1) | UA58481C2 (de) |
WO (1) | WO1995013312A1 (de) |
Families Citing this family (440)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US20010055581A1 (en) | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
HU230160B1 (hu) | 1996-02-09 | 2015-09-28 | Swedish Orphan Biovitrum Ab (Publ) | Interleukin-I inhibitort és kontrollált felszabadulású polimerként hialuronant tartalmazó készítmények |
US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US6566406B1 (en) * | 1998-12-04 | 2003-05-20 | Incept, Llc | Biocompatible crosslinked polymers |
AU4648697A (en) * | 1996-09-23 | 1998-04-14 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
US8003705B2 (en) * | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
US6072040A (en) | 1996-10-15 | 2000-06-06 | Medical Analysis Systems, Inc. | Stabilized conjugates of uncomplexed subunits of multimeric proteins |
EP2002846B1 (de) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten |
PT942740E (pt) | 1996-12-06 | 2004-01-30 | Amgen Inc | Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf |
US6743248B2 (en) | 1996-12-18 | 2004-06-01 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
US20040176801A1 (en) * | 1997-03-12 | 2004-09-09 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
US20030191496A1 (en) * | 1997-03-12 | 2003-10-09 | Neomend, Inc. | Vascular sealing device with microwave antenna |
AU7282698A (en) * | 1997-05-15 | 1998-12-08 | Theratech, Inc. | Targeted delivery to t lymphocytes |
US6284246B1 (en) | 1997-07-30 | 2001-09-04 | The Procter & Gamble Co. | Modified polypeptides with high activity and reduced allergenicity |
US6251866B1 (en) | 1997-08-05 | 2001-06-26 | Watson Laboratories, Inc. | Conjugates targeted to the interleukin-2 receptor |
US6168784B1 (en) * | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
WO1999011202A1 (en) * | 1997-09-05 | 1999-03-11 | Icet, Inc. | Biomimetic calcium phosphate implant coatings and methods for making the same |
US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
US6066673A (en) * | 1998-03-12 | 2000-05-23 | The Procter & Gamble Company | Enzyme inhibitors |
JP4078032B2 (ja) | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル,コーポレイション | 近位の反応性基を持つポリ(エチレングリコール)誘導体 |
JP2002507426A (ja) | 1998-03-26 | 2002-03-12 | ザ、プロクター、エンド、ギャンブル、カンパニー | アミノ酸置換を有するセリンプロテアーゼ変異体 |
US6495136B1 (en) | 1998-03-26 | 2002-12-17 | The Procter & Gamble Company | Proteases having modified amino acid sequences conjugated to addition moieties |
US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6994686B2 (en) * | 1998-08-26 | 2006-02-07 | Neomend, Inc. | Systems for applying cross-linked mechanical barriers |
US6458147B1 (en) | 1998-11-06 | 2002-10-01 | Neomend, Inc. | Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue |
AU764144B2 (en) * | 1998-08-28 | 2003-08-14 | Gryphon Therapeutics, Inc. | Polyamide chains of precise length, methods to manufacture them and their conjugates |
US6551613B1 (en) * | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
BR9914023A (pt) | 1998-09-22 | 2001-06-26 | Procter & Gamble | Composição de esfregão e de máscara da pele de tratamento pessoal e processo para umedecimento da pele |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6830756B2 (en) * | 1998-11-06 | 2004-12-14 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
US6899889B1 (en) | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
US6949114B2 (en) | 1998-11-06 | 2005-09-27 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
US7279001B2 (en) * | 1998-11-06 | 2007-10-09 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
MXPA01007777A (es) | 1999-02-01 | 2003-10-06 | Eidgenoess Tech Hochschule | Bio-materiales formadas por reaccion de adicion nucleofila a grupos insaturados conjugados. |
US6958212B1 (en) * | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
WO2000078285A1 (en) * | 1999-06-18 | 2000-12-28 | University Of Medicine And Dentistry Of New Jersey | Controlled release of therapeutics by in-situ entrapment by matrix cross-linking |
CZ2002212A3 (cs) | 1999-07-22 | 2002-07-17 | The Procter & Gamble Company | Varianty subtilisinové proteasy mající aminokyselinové substituce v definovaných epitopových oblastech |
US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
CZ2002171A3 (cs) | 1999-07-22 | 2002-06-12 | The Procter & Gamble Company | Proteinázový konjugát, čistící prostředek a prostředek osobní péče |
JP2003505067A (ja) | 1999-07-22 | 2003-02-12 | ザ、プロクター、エンド、ギャンブル、カンパニー | 特定のエピトープ領域にアミノ酸欠失及び置換を有するサブチリシンプロテアーゼの変異体 |
US7008635B1 (en) * | 1999-09-10 | 2006-03-07 | Genzyme Corporation | Hydrogels for orthopedic repair |
US6303119B1 (en) | 1999-09-22 | 2001-10-16 | The Procter & Gamble Company | Personal care compositions containing subtilisin enzymes bound to water insoluble substrates |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
DE60139110D1 (de) | 2000-01-10 | 2009-08-13 | Maxygen Holdings Ltd | G-csf konjugate |
DK1257295T3 (da) | 2000-02-11 | 2009-08-10 | Bayer Healthcare Llc | Faktor VII eller VIIA-lignende molekyler |
JP2003533682A (ja) | 2000-05-15 | 2003-11-11 | テカン・トレーディング・アクチェンゲゼルシャフト | 双方向流動遠心ミクロ流体装置 |
ES2290142T3 (es) * | 2000-05-16 | 2008-02-16 | Bolder Biotechnology, Inc. | Metodos para replegamiento de proteinas que contiene residuos de cisteina libre. |
US7291673B2 (en) * | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
MXPA03000310A (es) * | 2000-07-12 | 2004-12-13 | Gryphon Therapeutics Inc | Quimiocinas sinteticas bioactivas, modificadas con polimeros y metodos para su elaboracion y uso. |
EP1318827A4 (de) * | 2000-09-08 | 2005-09-14 | Gryphon Therapeutics Inc | Durch polymere veränderte synthetische proteine |
US7118737B2 (en) * | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
EP1355965B1 (de) * | 2000-10-19 | 2012-09-19 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Verfahren zur herstellung von blockcopolymeren für multifunktionelle selbstorganisierende systeme |
AU2002220002B2 (en) | 2000-10-31 | 2006-12-14 | Evonik Corporation | Methods and compositions for enhanced delivery of bioactive molecules |
TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
DE60232434D1 (de) | 2001-02-27 | 2009-07-09 | Maxygen Aps | Neue interferon-beta-ähnliche moleküle |
US20030044468A1 (en) * | 2001-03-20 | 2003-03-06 | Francesco Cellesi | Two-phase processing of thermosensitive polymers for use as biomaterials |
US6538104B2 (en) * | 2001-04-27 | 2003-03-25 | Medical Analysis Systems, Inc. | Stabilization of cardiac troponin I subunits and complexes |
US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
CA2457876C (en) * | 2001-08-22 | 2011-10-11 | Bioartificial Gel Technologies Inc. | Process for the preparation of activated polyethylene glycols |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
EP2305311A3 (de) | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glykokonjugation von Peptiden |
ES2556338T3 (es) | 2001-10-10 | 2016-01-15 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7056500B2 (en) | 2001-10-18 | 2006-06-06 | Nektar Therapeutics Al, Corporation | Polymer conjugates of opioid antagonists |
CA2462819A1 (en) * | 2001-11-23 | 2003-05-30 | Simon Fredriksson | Method and kit for proximity probing with multivalent proximity probes |
RS55578B1 (sr) * | 2002-01-18 | 2017-06-30 | Biogen Ma Inc | Polimerna jedinjenja polialkilena i njihova upotreba |
US20030179692A1 (en) * | 2002-03-19 | 2003-09-25 | Yoshitaka Ohotomo | Storage medium |
US8282912B2 (en) * | 2002-03-22 | 2012-10-09 | Kuros Biosurgery, AG | Compositions for tissue augmentation |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
DK1941867T3 (da) | 2002-06-07 | 2012-01-02 | Dyax Corp | Polypeptid med modificeret Kunitz domæne |
PL211175B1 (pl) | 2002-06-21 | 2012-04-30 | Novo Nordisk Healthcare Ag | Koniugat polipeptydu czynnika VII, sposób wytwarzania takiego koniugatu, zawierający taki koniugat preparat farmaceutyczny oraz zastosowanie takiego koniugatu |
DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
US7034127B2 (en) * | 2002-07-02 | 2006-04-25 | Genzyme Corporation | Hydrophilic biopolymer-drug conjugates, their preparation and use |
CA2497777A1 (en) * | 2002-09-05 | 2004-03-18 | The General Hospital Corporation | Modified asialo-interferons and uses thereof |
KR20050083678A (ko) * | 2002-09-05 | 2005-08-26 | 더 제너럴 하스피탈 코포레이션 | 아시알로-인터페론과 간암의 치료 |
WO2004022629A2 (en) | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
CN1312279C (zh) * | 2002-11-07 | 2007-04-25 | 连云港新阳医药有限公司 | 聚乙二醇修饰门冬酰胺酶的制备方法 |
CA2511815A1 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
NZ541124A (en) * | 2002-12-26 | 2008-08-29 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
EP1616003A4 (de) * | 2002-12-30 | 2007-06-20 | Gryphon Therapeutics Inc | Wasserlösliche thioester- und selenoesterverbindungen sowie verfahren zur herstellung und verwendung davon |
US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
ES2352337T5 (es) * | 2003-01-06 | 2017-08-11 | Nektar Therapeutics | Derivados tiol-selectivos de un polimero soluble en agua |
US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
CA2509939C (en) * | 2003-01-06 | 2013-05-21 | Nektar Therapeutics Al, Corporation | Thiol-selective water-soluble polymer derivatives |
CN102139114A (zh) | 2003-02-26 | 2011-08-03 | 尼克塔治疗公司 | 聚合物-因子viii部分缀合物 |
AU2004218354B2 (en) * | 2003-03-05 | 2009-10-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
US7610156B2 (en) * | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
AU2004227937B2 (en) * | 2003-03-31 | 2007-09-20 | Xencor, Inc | Methods for rational pegylation of proteins |
US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
CA2521381C (en) | 2003-04-11 | 2020-05-26 | Kenneth Hinds | Method for preparation of site-specific protein conjugates |
WO2004091517A2 (en) | 2003-04-15 | 2004-10-28 | Smithkline Beecham Corporation | Conjugates comprising human il-18 and substitution mutants thereof |
ES2380093T3 (es) | 2003-05-09 | 2012-05-08 | Biogenerix Ag | Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana |
US20040249119A1 (en) * | 2003-06-05 | 2004-12-09 | Fox Martin Edward | Novel mPEG propionaldehyde precursor |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
ES2341960T3 (es) | 2003-07-22 | 2010-06-30 | Nektar Therapeutics | Procedimientos para preparar polimeros funcionalizados a partir de alcoholes polimericos. |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
PT1663281E (pt) * | 2003-08-29 | 2014-03-17 | Dyax Corp | Inibidores de proteases poli-peguilados |
PL1675622T3 (pl) | 2003-09-17 | 2017-11-30 | Nektar Therapeutics | Proleki na bazie wieloramiennego polimeru |
EP1675620B1 (de) * | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymerderivate |
US7524813B2 (en) * | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
WO2005035565A1 (en) | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Il-21 derivatives |
EP1675871A2 (de) | 2003-10-10 | 2006-07-05 | Xencor Inc. | Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha |
ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
WO2005044836A2 (de) | 2003-11-05 | 2005-05-19 | Genovoxx Gmbh | Makromolekulare nukleotidverbindungen und methoden zu deren anwendung |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
ES2445948T3 (es) * | 2003-11-24 | 2014-03-06 | Ratiopharm Gmbh | Eritropoyetina glicopegilada |
EP1694301A4 (de) | 2003-12-02 | 2009-11-18 | Cytimmune Sciences Inc | Verfahren und zusammensetzungen zur herstellung von monoklonalen antikörpern |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
CN101072789B (zh) * | 2004-01-08 | 2013-05-15 | 生物种属学股份公司 | 肽的o-连接的糖基化 |
US20050175584A1 (en) * | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
AU2005319099B2 (en) * | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
WO2005074524A2 (en) * | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
KR100580644B1 (ko) * | 2004-02-16 | 2006-05-16 | 삼성전자주식회사 | 생물분자를 고체 기판상에 비공유적으로 고정화 하는 방법및 그에 의하여 제조되는 마이크로어레이 |
US7351787B2 (en) * | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
MXPA06010505A (es) * | 2004-03-15 | 2006-12-19 | Nektar Therapeutics Al Corp | Composiciones y conjugados, basados en polimeros, de inhibidores de ingreso de vih. |
JP2007531715A (ja) * | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合fgf−21化合物 |
WO2005115477A2 (en) | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
KR101699142B1 (ko) * | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
EP2359842A1 (de) | 2004-07-14 | 2011-08-24 | University of Utah Research Foundation | Netrin verwandten zusammensetzungen und verwendungen |
EP1771573A4 (de) * | 2004-07-21 | 2009-02-18 | Ambrx Inc | Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide |
EP1799249A2 (de) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegyliertes interferon alpha |
EP2301963A1 (de) | 2004-09-23 | 2011-03-30 | Vasgene Therapeutics, Inc. | Polypeptidverbindungen zur Hemmung von Angiogenese und Tumorwachstum |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US7612153B2 (en) * | 2004-10-25 | 2009-11-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) and uses thereof |
EP1814573B1 (de) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
CN101111267B (zh) | 2004-12-21 | 2012-12-05 | 尼克塔治疗公司 | 稳定的聚合物巯基试剂 |
CN103290084A (zh) | 2004-12-22 | 2013-09-11 | Ambrx公司 | 表达和纯化重组人类生长激素的方法 |
EP1828224B1 (de) | 2004-12-22 | 2016-04-06 | Ambrx, Inc. | Zusammensetzungen mit, verfahren mit und verwendungen von nichtnatürlichen aminosäuren und polypeptiden |
JP4990792B2 (ja) * | 2004-12-22 | 2012-08-01 | アンブレツクス・インコーポレイテツド | アミノアシル−tRNAシンテターゼの組成物およびこの使用 |
MX2007007587A (es) * | 2004-12-22 | 2007-12-11 | Ambrx Inc | Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural. |
NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
AU2006213822B2 (en) * | 2005-02-09 | 2011-05-26 | Covidien Lp | Synthetic sealants |
EP1868652A2 (de) | 2005-04-05 | 2007-12-26 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Verfahren zur abschirmung von funktionalen stellen oder epitopen auf proteinen |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP1885403B1 (de) * | 2005-04-12 | 2013-05-08 | Nektar Therapeutics | Poly(ethylenglykol)-Konjugate von Lysostaphin |
KR20080013878A (ko) | 2005-04-18 | 2008-02-13 | 노보 노르디스크 에이/에스 | Il-21 변이체 |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CA2608311C (en) | 2005-05-13 | 2012-11-27 | Eli Lilly And Company | Glp-1 pegylated compounds |
JP5216580B2 (ja) * | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
EP1891141B1 (de) * | 2005-05-31 | 2016-11-16 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis |
JP2008541769A (ja) * | 2005-06-03 | 2008-11-27 | アンブレツクス・インコーポレイテツド | 改善されたヒトインターフェロン分子及びそれらの使用 |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
AU2006259525B2 (en) | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
EP1926768B1 (de) | 2005-07-18 | 2011-09-14 | Nektar Therapeutics | Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
MX2008002149A (es) * | 2005-08-18 | 2008-04-22 | Ambrx Inc | Composiciones de arnt y sus usos. |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
RS51998B (en) * | 2005-11-08 | 2012-04-30 | Ambrx Inc. | ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES |
CA2626522A1 (en) * | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
SG170116A1 (en) * | 2005-12-14 | 2011-04-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8293869B2 (en) * | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
US7743730B2 (en) * | 2005-12-21 | 2010-06-29 | Lam Research Corporation | Apparatus for an optimized plasma chamber grounded electrode assembly |
EP1981525B1 (de) | 2005-12-30 | 2015-01-21 | Zensun (Shanghai) Science and Technology Limited | Verlängerte freisetzung von neuregulin für verbesserte herzfunktion |
CN101400363B (zh) | 2006-01-18 | 2012-08-29 | 昌达生物科技公司 | 具有增强的稳定性的药物组合物 |
MX2008010841A (es) | 2006-02-21 | 2008-10-27 | Nektar Therapeutics Al Corp | Polimeros degradables segmentados y conjugados hechos de los mismos. |
EP2004231A4 (de) | 2006-04-07 | 2013-07-10 | Nektar Therapeutics | Konjugate eines anti-tnf-alpha-antikörpers |
EP2574624A1 (de) | 2006-04-20 | 2013-04-03 | Amgen Inc. | GLP-1-Verbindungen |
US7560588B2 (en) * | 2006-04-27 | 2009-07-14 | Intezyne Technologies, Inc. | Poly(ethylene glycol) containing chemically disparate endgroups |
CN101484576A (zh) | 2006-05-24 | 2009-07-15 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内半寿期的因子ix类似物 |
JP2009541333A (ja) | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 修飾リボヌクレアーゼ |
US8242179B2 (en) * | 2006-06-23 | 2012-08-14 | Surmodics, Inc. | Hydrogel-based joint repair system and method |
EP2049151A4 (de) | 2006-07-17 | 2010-03-24 | Quintessence Biosciences Inc | Verfahren und zusammensetzungen zur behandlung von krebs |
JP2009544327A (ja) * | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | O−結合型グリコシル化配列によるペプチドのグリコシル化 |
CN101511856B (zh) * | 2006-09-08 | 2016-01-20 | Ambrx公司 | 脊椎动物细胞中抑制因子trna的转录 |
JP5399906B2 (ja) * | 2006-09-08 | 2014-01-29 | アンブルックス,インコーポレイテッド | 脊椎動物細胞用のハイブリッドサプレッサーtrna |
CN106008699A (zh) | 2006-09-08 | 2016-10-12 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
LT2068907T (lt) * | 2006-10-04 | 2018-01-10 | Novo Nordisk A/S | Glicerolio sujungti pegilinti sacharidai ir glikopeptidai |
AU2007343796A1 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
CA2666426A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
KR20090110295A (ko) | 2006-11-22 | 2009-10-21 | 에드넥서스, 어 브리스톨-마이어스 스퀴브 알&디 컴파니 | Igf-ir을 포함하는 티로신 키나제 수용체에 대한 공학처리된 단백질에 기반한 표적화 치료제 |
KR101441709B1 (ko) * | 2006-11-30 | 2014-09-18 | 넥타르 테라퓨틱스 | 중합체 컨쥬게이트의 제조 방법 |
PT2121751T (pt) | 2006-12-08 | 2017-04-18 | Lexicon Pharmaceuticals Inc | Anticorpos monoclonais contra angptl3 |
WO2008076933A2 (en) | 2006-12-14 | 2008-06-26 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
EP2117603A2 (de) * | 2006-12-19 | 2009-11-18 | Bracco International B.V. | Targeting und therapeutische verbindungen und gasgefüllte mikrovesikel mit diesen verbindungen |
EP2097140B1 (de) | 2006-12-20 | 2012-09-26 | Arkema Inc. | Polymer-verkapselung und/oder bindung |
EP2121754B1 (de) | 2007-01-18 | 2015-02-11 | Eli Lilly and Company | Pegyliertes amyloid beta fab |
ES2558928T3 (es) | 2007-01-31 | 2016-02-09 | Dana-Farber Cancer Institute, Inc. | Péptidos p53 estabilizados y usos de los mismos |
WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
US20090227981A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090227689A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
ES2381639T3 (es) | 2007-04-13 | 2012-05-30 | Kuros Biosurgery Ag | Sellante polimérico para tejidos |
AU2008247815B2 (en) * | 2007-05-02 | 2012-09-06 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
WO2008153745A2 (en) | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | ヌクレオチド糖の改良製造法 |
US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
US9125807B2 (en) * | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
KR20100046185A (ko) * | 2007-08-09 | 2010-05-06 | 다이이찌 산쿄 가부시키가이샤 | 데스 도메인 함유 수용체 발현 세포에 아포토시스를 유도하는 이뮤노리포솜 |
US8067028B2 (en) * | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
WO2009026334A2 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
AU2008302035A1 (en) * | 2007-09-21 | 2009-03-26 | Cytimmune Sciences, Inc. | Nanotherapeutic colloidal metal compositions and methods |
US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
JP2010540681A (ja) * | 2007-10-08 | 2010-12-24 | クインテッセンス バイオサイエンシズ,インコーポレーテッド | リボヌクレアーゼに基づく治療のための組成物及び方法 |
EP2214716B1 (de) * | 2007-10-23 | 2021-11-17 | Nektar Therapeutics | Auf hydroxyapatite gezielrichtete multiarm polymere und daraus hergestellte konjugate |
WO2009062151A1 (en) * | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
US20090123519A1 (en) * | 2007-11-12 | 2009-05-14 | Surmodics, Inc. | Swellable hydrogel matrix and methods |
WO2009064459A2 (en) * | 2007-11-12 | 2009-05-22 | Intradigm Corporation | Heterobifunctional polyethylene glycol reagents |
NZ603812A (en) | 2007-11-20 | 2014-06-27 | Ambrx Inc | Modified insulin polypeptides and their uses |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
CN103497246B (zh) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
US20090226531A1 (en) * | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
CA3096629A1 (en) | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
EA019289B1 (ru) | 2008-04-21 | 2014-02-28 | Тайджен Байотекнолоджи Ко., Лтд. | Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
EP2293818B1 (de) * | 2008-05-16 | 2021-04-28 | Nektar Therapeutics | Konjugate aus butyrylcholinesterase und eines polymers |
PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
CN102099058B (zh) * | 2008-07-21 | 2014-10-22 | 宝力泰锐克斯有限公司 | 用于缀合生物分子的新试剂和方法 |
PE20110426A1 (es) | 2008-07-23 | 2011-07-01 | Ambrx Inc | Polipeptidos g-csf bovinos modificados |
MX2011001583A (es) | 2008-08-11 | 2011-04-04 | Nektar Therapeutics | Conjugados de alcanoato polimericos de multiples brazos. |
WO2010033205A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
EP2344199A1 (de) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Polymer-konjugate von thymosin-alpha1-peptiden |
EP2334334A1 (de) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymerkonjugate von nesiritid-peptiden |
WO2010033218A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
WO2010033204A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of c-peptides |
WO2010033221A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
US20110237524A1 (en) * | 2008-09-19 | 2011-09-29 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
WO2010033223A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
US20110166063A1 (en) | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
WO2010033222A2 (en) * | 2008-09-19 | 2010-03-25 | Netkar Therapeutics | Polymer conjugates of ziconotide peptides |
WO2010033224A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
WO2010042145A1 (en) * | 2008-09-19 | 2010-04-15 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
CN102224238B (zh) | 2008-09-26 | 2015-06-10 | Ambrx公司 | 非天然氨基酸复制依赖性微生物和疫苗 |
CN107022020A (zh) | 2008-09-26 | 2017-08-08 | Ambrx公司 | 修饰的动物促红细胞生成素多肽和其用途 |
JP2012504423A (ja) | 2008-10-01 | 2012-02-23 | クインテッセンス バイオサイエンシズ,インコーポレーテッド | 治療用リボヌクレアーゼ |
TW201021855A (en) | 2008-11-13 | 2010-06-16 | Taigen Biotechnology Co Ltd | Lyophilization formulation |
US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
SG172064A1 (en) | 2008-12-09 | 2011-07-28 | Halozyme Inc | Extended soluble ph20 polypeptides and uses thereof |
GB0823309D0 (en) * | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
AU2010203712A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
WO2010080720A2 (en) | 2009-01-12 | 2010-07-15 | Nektar Therapeutics | Conjugates of a lysosomal enzyme moiety and a water soluble polymer |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
WO2010100430A1 (en) * | 2009-03-04 | 2010-09-10 | Polytherics Limited | Conjugated proteins and peptides |
US8067201B2 (en) * | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
RS56496B1 (sr) | 2009-06-09 | 2018-01-31 | Prolong Pharmaceuticals Llc | Kompozicije hemoglobina |
CA2770149A1 (en) | 2009-08-05 | 2011-02-10 | Pieris Ag | Controlled release formulations of lipocalin muteins |
HUE028832T2 (en) | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation |
EP2494073B1 (de) | 2009-10-26 | 2017-11-29 | AGCT GmbH | Konjugate von nukleotiden und methoden zu deren anwendung |
AU2010313456A1 (en) | 2009-10-30 | 2012-05-17 | Ntf Therapeutics, Inc. | Improved neurturin molecules |
CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
CA2784800A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
WO2011085103A2 (en) | 2010-01-06 | 2011-07-14 | Dyax Corp. | Plasma kallikrein binding proteins |
CN102161754B (zh) * | 2010-02-13 | 2012-06-13 | 华中科技大学同济医学院附属协和医院 | 枝化状聚乙二醇衍生物的功能化修饰方法 |
CA2791841C (en) | 2010-03-05 | 2023-01-03 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
JP6066900B2 (ja) | 2010-04-26 | 2017-01-25 | エータイアー ファーマ, インコーポレイテッド | システイニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CA2797362C (en) | 2010-04-27 | 2020-12-08 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
JP6008837B2 (ja) | 2010-04-28 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | アラニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
CA2797393C (en) | 2010-04-29 | 2020-03-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
WO2011139854A2 (en) | 2010-04-29 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
EP2566495B1 (de) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-alpha-trna-synthetasen |
JP6008841B2 (ja) | 2010-05-03 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | メチオニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CA2797277C (en) | 2010-05-03 | 2021-02-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
EP2566499B1 (de) | 2010-05-04 | 2017-01-25 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex |
JP2013528374A (ja) | 2010-05-10 | 2013-07-11 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Vla4のポリペプチド阻害剤 |
CN103200953B (zh) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
EP2571896A4 (de) | 2010-05-17 | 2014-01-08 | Cebix Inc | Pegyliertes c-peptid |
JP6027965B2 (ja) | 2010-05-17 | 2016-11-16 | エータイアー ファーマ, インコーポレイテッド | ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
WO2011150133A2 (en) | 2010-05-26 | 2011-12-01 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
WO2011153277A2 (en) | 2010-06-01 | 2011-12-08 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
CA2806058C (en) | 2010-07-20 | 2016-09-13 | Halozyme, Inc. | Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
TWI707926B (zh) | 2010-07-30 | 2020-10-21 | 瑞士商愛爾康公司 | 可易於使用之聚矽氧水凝膠隱形鏡片 |
RS59193B1 (sr) | 2010-08-17 | 2019-10-31 | Ambrx Inc | Modifikovani polipeptidi relaksina i njihova primena |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
EP2608801B1 (de) | 2010-08-25 | 2019-08-21 | aTyr Pharma, Inc. | Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von tyrosyl-trna-synthetasen |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
AU2011325990C1 (en) | 2010-11-12 | 2017-06-08 | Nektar Therapeutics | Conjugates of an IL-2 moiety and a polymer |
CA2817568A1 (en) | 2010-11-12 | 2012-05-18 | The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer | Cancer therapies and diagnostics |
SG189982A1 (en) | 2010-11-24 | 2013-06-28 | Lexicon Pharmaceuticals Inc | Antibodies to notum pectinacetylesterase |
US20140371258A1 (en) | 2010-12-17 | 2014-12-18 | Nektar Therapeutics | Water-Soluble Polymer Conjugates of Topotecan |
EP2654795B1 (de) | 2010-12-21 | 2018-03-07 | Nektar Therapeutics | Mehrarmige polymer prodrug-konjugate aus verbindungen auf pemetrexed-basis |
WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
AP2013007173A0 (en) | 2011-03-16 | 2013-10-31 | Amgen Inc | Potent and selective inhibitors of NAV1.3 and NAV1.7 |
EP2709669A1 (de) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Verfahren zur aufrechterhaltung der pegylierung von polypeptiden |
WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
EP2720722A4 (de) | 2011-06-16 | 2014-12-03 | Univ Hong Kong Science & Techn | Molekül mit mehreren vinylsulfonen |
EP2720712B1 (de) | 2011-06-17 | 2016-03-02 | Halozyme, Inc. | Stabile formulierungen eines hyaluronan-abbauenden enzyms |
US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
WO2012174480A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
AU2012280474A1 (en) | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
PT2717917T (pt) | 2011-07-05 | 2016-07-27 | Bioasis Technologies Inc | Conjugados de anticorpos p97 |
WO2013020079A2 (en) | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
US20130071394A1 (en) | 2011-09-16 | 2013-03-21 | John K. Troyer | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
CN104093415B (zh) | 2011-10-24 | 2017-04-05 | 哈洛齐梅公司 | 抗乙酰透明质酸剂疗法的同伴诊断剂及其使用方法 |
US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US8962553B2 (en) | 2011-11-17 | 2015-02-24 | Cebix Ab | Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide |
AU2012347926B2 (en) | 2011-12-05 | 2018-03-15 | Incept, Llc | Medical organogel processes and compositions |
EP2858661B1 (de) | 2011-12-29 | 2020-04-22 | Dana-Farber Cancer Institute, Inc. | Stabilisierte antivirale fusionsspiralen |
WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
KR20140123571A (ko) | 2012-02-16 | 2014-10-22 | 에이티와이알 파마, 인코포레이티드 | 자가면역 및 염증성 질환의 치료를 위한 히스티딜trna 신테타제 |
TR201802761T4 (tr) | 2012-03-30 | 2018-03-21 | Univ Oklahoma | Yüksek molekül ağırlıklı heparosan polimerler ve bunların üretimine ve kullanımına yönelik metotlar. |
EP2838577B1 (de) | 2012-04-02 | 2019-02-27 | SurModics, Inc. | Hydrophile polymerbeschichtungen für medizinische artikel mit einem visualisierungsteil |
PT2833905T (pt) | 2012-04-04 | 2018-08-06 | Halozyme Inc | Terapia de combinação com hialuronidase e um taxano dirigido a tumor |
US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
KR102163408B1 (ko) | 2012-05-31 | 2020-10-08 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
CA2875989A1 (en) | 2012-06-08 | 2013-12-12 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
CN109503714A (zh) | 2012-06-21 | 2019-03-22 | 索伦托治疗有限公司 | 与c-Met结合的抗原结合蛋白 |
CN105051065A (zh) | 2012-06-22 | 2015-11-11 | 索伦托治疗有限公司 | 与ccr2结合的抗原结合蛋白 |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
AU2013296557B2 (en) | 2012-07-31 | 2019-04-18 | Bioasis Technologies Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
HUE045227T2 (hu) | 2012-08-31 | 2019-12-30 | Sutro Biopharma Inc | Azido csoportot tartalmazó módosított aminosavak |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
EP2916835A4 (de) | 2012-11-12 | 2016-07-27 | Redwood Bioscience Inc | Verbindungen und verfahren zur herstellung eines konjugats |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
WO2014078733A1 (en) | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
US20160067347A1 (en) | 2012-12-20 | 2016-03-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
TW201446792A (zh) | 2013-03-12 | 2014-12-16 | Amgen Inc | Nav1.7之強效及選擇性抑制劑 |
NZ711373A (en) | 2013-03-13 | 2020-07-31 | Bioasis Technologies Inc | Fragments of p97 and uses thereof |
US10308926B2 (en) | 2013-03-15 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Stablized EZH2 peptides |
CA2906775A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
CA2906740A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2015013510A1 (en) | 2013-07-25 | 2015-01-29 | Ecole Polytechnique Federale De Lausanne Epfl | High aspect ratio nanofibril materials |
AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
WO2015073758A1 (en) | 2013-11-15 | 2015-05-21 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
US9493413B2 (en) | 2013-11-27 | 2016-11-15 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
CN105934257B (zh) | 2013-12-06 | 2020-10-09 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
CA2948864C (en) | 2014-05-14 | 2023-10-17 | Karl E. Griswold | Deimmunized lysostaphin and methods of use |
AU2015274574B2 (en) | 2014-06-10 | 2019-10-10 | Amgen Inc. | Apelin polypeptides |
US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
EP3646879B1 (de) | 2014-08-12 | 2024-04-03 | Massachusetts Institute Of Technology | Synergistische tumorbehandlung mit integrin-bindendem fc-fusionsprotein und ein immun-checkpoint inhibitor |
WO2016028523A2 (en) | 2014-08-22 | 2016-02-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr3 |
HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
NZ746680A (en) | 2014-10-14 | 2020-07-31 | Halozyme Inc | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
SG11201701384XA (en) | 2014-10-14 | 2017-03-30 | Polytherics Ltd | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
KR102513926B1 (ko) * | 2014-10-24 | 2023-03-23 | 폴리테릭스 리미티드 | 접합체 및 접합 시약 |
PT3412302T (pt) | 2014-10-24 | 2021-06-09 | Bristol Myers Squibb Co | Polipéptidos de fgf-21 modificados e utilizações dos mesmos |
GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
EP3229851A4 (de) | 2014-12-09 | 2018-08-01 | Tangible Science LLC | Beschichtung einer medizinischen vorrichtung mit biokompatibler schicht |
WO2016149613A2 (en) | 2015-03-18 | 2016-09-22 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
AU2016287754B2 (en) | 2015-07-02 | 2021-02-25 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
EP3341008A4 (de) | 2015-08-28 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | An bfl-1 bindende peptide |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
CA3013051A1 (en) | 2016-01-29 | 2017-08-03 | Heyue Zhou | Antigen binding proteins that bind pd-l1 |
US20170247423A1 (en) | 2016-02-29 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
WO2018017922A2 (en) | 2016-07-22 | 2018-01-25 | Massachusetts Institute Of Technology | Selective bfl-1 peptides |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
EP3503924B1 (de) | 2016-08-26 | 2022-12-14 | Dana-Farber Cancer Institute, Inc. | Bcl-w-polypeptide und mimetika zur behandlung oder prävention von chemotherapieinduzierter peripherer neuropathie und hörverlust |
CN110637027A (zh) | 2017-02-08 | 2019-12-31 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
WO2018170299A1 (en) | 2017-03-15 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of prokaryotic gene transcription and uses thereof |
WO2018172503A2 (en) | 2017-03-24 | 2018-09-27 | Basf Se | Liquid laundry detergent comprising modified saccharide or polysaccharide |
BR112019027583A2 (pt) | 2017-06-22 | 2020-10-06 | Catalyst Biosciences, Inc. | polipeptídeos de serina protease 1 tipo membrana (mtsp-1) modificados e métodos de uso |
JP7305614B2 (ja) | 2017-07-19 | 2023-07-10 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
EP3684811A2 (de) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multispezifitätsbinder von cxc-chemokinen und ihre verwendung |
EP3688007A1 (de) | 2017-09-27 | 2020-08-05 | The University of York | Biokonjugation von polypeptiden |
EP3724216A1 (de) | 2017-12-15 | 2020-10-21 | Dana Farber Cancer Institute, Inc. | Durch stabilisiertes peptid vermittelter zielgerichteter proteinabbau |
EP3737404A1 (de) | 2017-12-15 | 2020-11-18 | Dana Farber Cancer Institute, Inc. | Selektives targeting von apoptose-proteinen durch strukturstabilisierte und/oder cysteinreaktive noxa-peptide |
EP3732254A4 (de) | 2017-12-26 | 2021-12-22 | Becton, Dickinson and Company | Tiefe uv-erregbare wassersolvatisierte polymerfarbstoffe |
EP3749678A1 (de) | 2018-02-07 | 2020-12-16 | Dana Farber Cancer Institute, Inc. | Zellpermeable, geheftete peptidmodule zur zellulären abgabe |
EP3765852A1 (de) | 2018-03-14 | 2021-01-20 | Dana Farber Cancer Institute, Inc. | Stabilisierte peptide für den nachweis von biomarkern |
US10844228B2 (en) | 2018-03-30 | 2020-11-24 | Becton, Dickinson And Company | Water-soluble polymeric dyes having pendant chromophores |
WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
KR102167755B1 (ko) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
CA3107332A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies Inc. | Treatment of lymphatic metastases |
JP2021535140A (ja) | 2018-08-28 | 2021-12-16 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 抗cd3抗体葉酸生物複合体およびその使用 |
SG11202102427XA (en) | 2018-09-11 | 2021-04-29 | Ambrx Inc | Interleukin-2 polypeptide conjugates and their uses |
WO2020060975A1 (en) | 2018-09-17 | 2020-03-26 | Massachusetts Institute Of Technology | Peptides selective for bcl-2 family proteins |
EP3867265A1 (de) | 2018-10-19 | 2021-08-25 | Ambrx, Inc. | Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen |
US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
US20220075098A1 (en) * | 2018-12-19 | 2022-03-10 | Tangible Science, Inc. | Systems and methods of treating a hydrogel-coated medical device |
WO2020140101A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
WO2020154032A1 (en) | 2019-01-23 | 2020-07-30 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
EP3962933A1 (de) | 2019-04-18 | 2022-03-09 | Dana-Farber Cancer Institute, Inc. | Selektives targeting von ubiquitin- und ubiquitin-ähnlichen e1-aktivierenden enzymen durch strukturell stabilisierte peptide |
WO2020219323A1 (en) | 2019-04-26 | 2020-10-29 | The Procter & Gamble Company | Reduction of tooth staining derived from cationic antimicrobials |
EP4077361A1 (de) | 2019-12-16 | 2022-10-26 | Dana-Farber Cancer Institute, Inc. | Strukturstabilisierte oncolytische peptide und verwendungen davon |
AU2020408070A1 (en) | 2019-12-20 | 2022-06-09 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof |
EP4090674A4 (de) | 2020-01-14 | 2024-01-24 | Synthekine Inc | Vorgespannte il2-muteins-verfahren und -zusammensetzungen |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
EP4114431A2 (de) | 2020-03-04 | 2023-01-11 | Dana-Farber Cancer Institute, Inc. | Antivirale, strukturell stabilisierte sars-cov-2 peptide und verwendungen davon |
WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
AU2021258205A1 (en) | 2020-04-22 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ACE2 helix 1 peptides and uses thereof |
CA3179873A1 (en) | 2020-04-27 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
EP4199968A1 (de) | 2020-08-20 | 2023-06-28 | Ambrx, Inc. | Antikörper-tlr-agonist-konjugate, verfahren und verwendungen davon |
US20230330238A1 (en) | 2020-10-14 | 2023-10-19 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
EP4240395A1 (de) | 2020-11-05 | 2023-09-13 | Dana-Farber Cancer Institute, Inc. | Antivirale strukturell stabilisierte ebolaviruspeptide und verwendungen davon |
CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
IL311151A (en) | 2021-09-08 | 2024-04-01 | Dana Farber Cancer Inst Inc | Structurally clamped antiviral SARS-COV-2 peptide-cholesterol conjugates and uses thereof |
EP4155349A1 (de) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Wasserlösliche gelbe grünabsorbierende farbstoffe |
WO2023215784A1 (en) | 2022-05-04 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof |
WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3784524A (en) * | 1971-06-25 | 1974-01-08 | Grace W R & Co | Urethane/thioether-containing polyene composition and the reaction product thereof |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
CH586739A5 (de) * | 1973-10-17 | 1977-04-15 | Hoechst Ag | |
US4134887A (en) * | 1973-10-17 | 1979-01-16 | Hoechst Aktiengesellschaft | Phenyl-azo-phenyl dyestuffs |
US4179387A (en) * | 1974-03-12 | 1979-12-18 | Fuji Photo Film Co., Ltd. | Process for producing magnetic FE oxide |
IL47468A (en) * | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
DE2607766C3 (de) * | 1976-02-26 | 1978-12-07 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung von trägergebundenen biologisch aktiven Substanzen |
US4228019A (en) * | 1978-06-19 | 1980-10-14 | Texaco Development Corp. | Secondary recovery process |
US4473693A (en) * | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
US4430260A (en) * | 1979-02-27 | 1984-02-07 | Lee Weng Y | Penicillin-polyvinyl alcohol conjugate and process of preparation |
US4296097A (en) * | 1979-02-27 | 1981-10-20 | Lee Weng Y | Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor |
US4241199A (en) * | 1979-09-18 | 1980-12-23 | Union Carbide Corporation | Novel polyester diols |
US4280979A (en) * | 1979-09-18 | 1981-07-28 | Union Carbide Corporation | Copolymers, compositions, and articles, and methods for making same |
JPS585320A (ja) * | 1981-07-01 | 1983-01-12 | Toray Ind Inc | グラフト共重合体 |
US4973493A (en) * | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
JPS59204144A (ja) * | 1983-04-12 | 1984-11-19 | Daikin Ind Ltd | 新規含フッ素化合物およびその製法 |
SE470099B (sv) * | 1984-05-17 | 1993-11-08 | Jerker Porath | Sulfonaktiverade tioeteradsorbenter för separation av t ex protein |
SE454885B (sv) * | 1984-10-19 | 1988-06-06 | Exploaterings Ab Tbf | Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav |
US4616644A (en) * | 1985-06-14 | 1986-10-14 | Johnson & Johnson Products, Inc. | Hemostatic adhesive bandage |
EP0206448B1 (de) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist |
WO1987000056A1 (en) * | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4883864A (en) * | 1985-09-06 | 1989-11-28 | Minnesota Mining And Manufacturing Company | Modified collagen compound and method of preparation |
US4983494A (en) * | 1985-10-16 | 1991-01-08 | Fuji Photo Film Co., Ltd. | Image forming process including heating step |
CA1283046C (en) * | 1986-05-29 | 1991-04-16 | Nandini Katre | Tumor necrosis factor formulation |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4871785A (en) * | 1986-08-13 | 1989-10-03 | Michael Froix | Clouding-resistant contact lens compositions |
DE3628717A1 (de) * | 1986-08-23 | 1988-02-25 | Agfa Gevaert Ag | Haertungsmittel fuer proteine, eine damit gehaertete bindemittelschicht und eine solche schicht enthaltendes fotografisches aufzeichnungsmaterial |
US4931544A (en) * | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
DE3634525A1 (de) * | 1986-10-10 | 1988-04-21 | Miles Lab | Testmittel und indikatoren zum nachweis von thiolgruppen und verfahren zu deren herstellung |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5153265A (en) * | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
NL8800577A (nl) * | 1988-03-08 | 1989-10-02 | Stichting Tech Wetenschapp | Werkwijze voor het aanbrengen van een bloedcompatibele bekleding op polyetherurethaanvormstukken. |
GB8824592D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Purification process |
GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
WO1990015628A1 (en) * | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
US5171264A (en) * | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
DE69120821T2 (de) * | 1990-08-31 | 1997-01-23 | Univ Minnesota | Polyethylenglykol-Derivate für Festphasenanwendungen |
US5380536A (en) * | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
SE467308B (sv) * | 1990-10-22 | 1992-06-29 | Berol Nobel Ab | Fast yta belagd med ett hydrofilt ytterskikt med kovalent bundna biopolymerer, saett att framstaella en saadan yta och ett konjugat daerfoer |
RU2166955C2 (ru) * | 1991-01-18 | 2001-05-20 | Эмген Инк. | Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток |
ES2199935T3 (es) * | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
JPH06506217A (ja) * | 1991-03-18 | 1994-07-14 | エンゾン,インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
DK52791D0 (da) * | 1991-03-22 | 1991-03-22 | Kem En Tec As | Adsorptionsmatricer |
DK130991D0 (da) * | 1991-07-04 | 1991-07-04 | Immunodex K S | Polymere konjugater |
CA2112992C (en) * | 1991-07-04 | 2002-06-11 | Allan O. F. Lihme | Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone |
US5414135A (en) | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
EP0622394A1 (de) * | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung |
-
1993
- 1993-11-12 US US08/151,481 patent/US5446090A/en not_active Expired - Lifetime
-
1994
- 1994-11-14 RO ROA200000307A patent/RO121855B1/ro unknown
- 1994-11-14 CZ CZ19961375A patent/CZ295640B6/cs not_active IP Right Cessation
- 1994-11-14 UA UA96062250A patent/UA58481C2/uk unknown
- 1994-11-14 CN CN94194460A patent/CN1085689C/zh not_active Expired - Fee Related
- 1994-11-14 CA CA002176203A patent/CA2176203C/en not_active Expired - Fee Related
- 1994-11-14 HU HU9601253A patent/HU225649B1/hu not_active IP Right Cessation
- 1994-11-14 BR BR9408048A patent/BR9408048A/pt not_active Application Discontinuation
- 1994-11-14 KR KR1019960702507A patent/KR100225746B1/ko not_active IP Right Cessation
- 1994-11-14 AT AT95901226T patent/ATE215577T1/de not_active IP Right Cessation
- 1994-11-14 DE DE69430317T patent/DE69430317T2/de not_active Expired - Lifetime
- 1994-11-14 EP EP95901226A patent/EP0728155B1/de not_active Expired - Lifetime
- 1994-11-14 WO PCT/US1994/013013 patent/WO1995013312A1/en active IP Right Grant
- 1994-11-14 NZ NZ276313A patent/NZ276313A/en not_active IP Right Cessation
- 1994-11-14 ES ES95901226T patent/ES2173943T3/es not_active Expired - Lifetime
- 1994-11-14 SK SK608-96A patent/SK284527B6/sk not_active IP Right Cessation
- 1994-11-14 EE EE9600128A patent/EE03448B1/xx not_active IP Right Cessation
- 1994-11-14 DK DK95901226T patent/DK0728155T3/da active
- 1994-11-14 PL PL94314298A patent/PL180149B1/pl not_active IP Right Cessation
- 1994-11-14 RO RO96-00959A patent/RO118434B1/ro unknown
- 1994-11-14 EP EP01122161A patent/EP1176160A3/de not_active Withdrawn
- 1994-11-14 AU AU10548/95A patent/AU687937B2/en not_active Ceased
- 1994-11-14 RU RU96113123/04A patent/RU2176253C2/ru active
- 1994-11-14 JP JP07514031A patent/JP3114998B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/473,734 patent/US5739208A/en not_active Expired - Lifetime
-
1996
- 1996-05-06 BG BG100568A patent/BG63399B1/bg unknown
- 1996-05-10 FI FI962004A patent/FI117441B/fi not_active IP Right Cessation
- 1996-05-10 NO NO19961918A patent/NO315377B1/no not_active IP Right Cessation
-
1998
- 1998-02-23 US US09/027,679 patent/US5900461A/en not_active Expired - Lifetime
-
1999
- 1999-04-19 US US09/294,188 patent/US6610281B2/en not_active Expired - Fee Related
-
2002
- 2002-05-30 HK HK02104035.7A patent/HK1042312A1/zh unknown
-
2003
- 2003-08-25 US US10/647,621 patent/US6894025B2/en not_active Expired - Fee Related
-
2005
- 2005-04-22 US US11/112,118 patent/US7214366B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69430317D1 (de) | Wasserlösliche aktive sulfone von polyethylenglycolen | |
CA2174325A1 (en) | Non-antigenic branched polymer conjugates | |
CA2323048A1 (en) | Poly(ethylene glycol) derivatives with proximal reactive groups | |
CA2283939A1 (en) | Non-antigenic branched polymer conjugates | |
DE68906366T2 (de) | CD4-Polypeptidderivate. | |
DE69823055D1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
FR2710843B1 (fr) | Composition d'organopolysiloxane d'aspect gélifié, sans gélifiant, utilisable en cosmétique et dermatologie. | |
BR9105822A (pt) | Clatratos de peroxiacidos | |
ATE116135T1 (de) | Einschlusskomplex von nimesulide mit cyclodextrinen. | |
DK0400914T3 (da) | Landbrugsmæssige skumsammensætninger | |
MX9101393A (es) | Uso de marcadores moleculares en la reproduccion de arboles | |
DE3853547D1 (de) | Reversibel ausfällbare, wasserlösliche Polymerkonjugate, ihre Herstellung und Verwendung in der homogenen Katalyse. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NEKTAR THERAPEUTICS AL,CORP., HUNTSVILLE, ALA., US |
|
R082 | Change of representative |
Ref document number: 728155 Country of ref document: EP Representative=s name: VON KREISLER SELTING WERNER, DE |
|
R081 | Change of applicant/patentee |
Ref document number: 728155 Country of ref document: EP Owner name: NEKTAR THERAPEUTICS, US Free format text: FORMER OWNER: NEKTAR THERAPEUTICS AL,CORP., HUNTSVILLE, US Effective date: 20121113 |
|
R082 | Change of representative |
Ref document number: 728155 Country of ref document: EP Representative=s name: VON KREISLER SELTING WERNER, DE Effective date: 20121113 |